Avantika Singh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Avantika Singh has a total of 87 co-authors. Here are the top co-authors by number of shared publications:
- Christina Briscoe Abath
Department of Neurology, Boston Children's Hospital, Boston, Massachusetts
5 shared publications - Debopam Samanta
Division of Pediatric Neurology, Department of Pediatrics University of Arkansas for Medical Sciences Little Rock Arkansas USA
5 shared publications Chellamani Harini
Department of Neurology Boston Children’s Hospital Boston Massachusetts USA
3 shared publicationsStephanie Donatelli
Department of Neurology, Boston Children's Hospital, Boston, Massachusetts
3 shared publications- Akshat Katyayan
Division of Pediatric Neurology and Developmental Neuroscience, Texas Children’s Hospital Baylor College of Medicine Houston Texas USA
2 shared publications - Amanda G. Sandoval Karamian
Division of Pediatric Neurology, Department of Pediatrics University of Utah School of Medicine and Intermountain Primary Children’s Health Salt Lake City Utah USA
2 shared publications
Latest Publications
- 11 September 2026
- Published by SAGE Publications in Journal of Child Neurology
- Vol. 41 (10) , 1422-1439
Caring Across Languages: Clinician Perceptions of Variability in US Pediatric Outpatient Epilepsy Care
Little is known about outpatient language access practices in the United States for children with epilepsy whose families use languages other than English (LOE) for medical care. The Pediatric Epilepsy Research Consortium (PERC) aimed to characterize clinician perceptions of institutional practices by developing and conducting a descriptive survey. We weighted statistical outcomes to equally represent clinician opinion from each center and conducted deductive thematic analysis of open-ended responses. One hundred clinicians from 40 institutions (53.3% institutional response rate) completed the survey. Access to both interpretation and translation services was uneven across PERC institutions. Seizure action plans in all common LOE were available at 15.2% of centers. Despite access to professional interpreters, 61.2% reported using nonprofessional interpretation at times. Qualitative themes included clinician burden, necessary resources, language certification practices, nonprofessional interpretation, translation delays, languages of lesser diffusion, technology use, trust in remote interpretation, language concordance, and perceptions of certification requirements. Findings highlight the need for interventions and guidelines to promote language-access for children with epilepsy whose families use LOE.
- 11 September 2026
- Published by SAGE Publications in Journal of Child Neurology
- Vol. 41 (10) , 1422-1439
Caring Across Languages: Clinician Perceptions of Variability in US Pediatric Outpatient Epilepsy Care
Little is known about outpatient language access practices in the United States for children with epilepsy whose families use languages other than English (LOE) for medical care. The Pediatric Epilepsy Research Consortium (PERC) aimed to characterize clinician perceptions of institutional practices by developing and conducting a descriptive survey. We weighted statistical outcomes to equally represent clinician opinion from each center and conducted deductive thematic analysis of open-ended responses. One hundred clinicians from 40 institutions (53.3% institutional response rate) completed the survey. Access to both interpretation and translation services was uneven across PERC institutions. Seizure action plans in all common LOE were available at 15.2% of centers. Despite access to professional interpreters, 61.2% reported using nonprofessional interpretation at times. Qualitative themes included clinician burden, necessary resources, language certification practices, nonprofessional interpretation, translation delays, languages of lesser diffusion, technology use, trust in remote interpretation, language concordance, and perceptions of certification requirements. Findings highlight the need for interventions and guidelines to promote language-access for children with epilepsy whose families use LOE.
- Open Access
- 8 August 2026
- Published by Wiley in Epilepsia Open
- Vol. 11 (5) , 1478-1489
Management of Infantile Epileptic Spasms Syndrome: A survey of US pediatric hospitals
Objective: To evaluate the management practices of Infantile Epileptic Spasms Syndrome (IESS) across tertiary pediatric hospitals in the United States using a survey‐based approach. Methods: A 21‐question survey focused on management setting, work‐up, follow‐up and treatment was created and sent to 45 member institutions of the Pediatric Epilepsy Research Consortium (PERC). Results were analyzed by a working group of PERC focused on IESS. Results: Thirty‐three institutions completed the survey. Most institutions (91%) managed new‐onset IESS in‐patient, with 76% using overnight video EEG (vEEG) monitoring for diagnosis. Nearly all (> 90%) obtained an MRI brain and genetic testing at initial diagnosis. The most common modalities of genetic evaluation were an epilepsy panel (47%) and trio whole exome sequencing (44%). For assessment of response at the first follow‐up, 45% used extended vEEG (1–6 h), with 36% continuing to obtain overnight vEEG. The 2021 BASED score (Burden of Amplitude and Epileptiform Discharges) was the preferred method of assessing response (58%) compared to resolution of hypsarrhythmia (39%). High‐dose prednisolone was the first treatment for most institutions, irrespective of the etiology (apart from Tuberous Sclerosis Complex). Combined treatment (hormonal + vigabatrin) was less commonly used as first treatment (9%–12%, depending on etiology). Most institutions (63%) looked for failure of both hormonal therapy and vigabatrin (sequential or combined) before pursuing surgical treatment in patients with identifiable brain MRI lesions, but would also consider surgical treatment in patients with remission of electro‐clinical epileptic spasms but continued epileptiform EEGs. Significance: There are areas of consensus and variability in management of IESS in US institutions. Updated consensus guidelines addressing the comprehensive management of IESS are needed to help standardize and optimize care in these patients. Plain Language Summary: Infantile Epileptic Spasms Syndrome requires prompt diagnosis and initiation of appropriate treatment to improve developmental outcomes. In this survey of tertiary pediatric centers in the United States, we found areas of consensus (use of overnight video EEG at initial diagnosis, use of high‐dose prednisolone as initial treatment, preference for sequential as opposed to combination therapy, use of the 2021 BASED score for EEG evaluation, and the early consideration of epilepsy surgery) and variability (type of genetic testing for diagnosis, choice of second and third treatments, use of antiseizure medications for persistently epileptic EEG) in management of these patients.
- 8 August 2026
- Published by Wiley in Epilepsia Open
- Vol. 11 (5) , 1478-1489
Open AccessManagement of Infantile Epileptic Spasms Syndrome: A survey of US pediatric hospitals
Objective: To evaluate the management practices of Infantile Epileptic Spasms Syndrome (IESS) across tertiary pediatric hospitals in the United States using a survey‐based approach. Methods: A 21‐question survey focused on management setting, work‐up, follow‐up and treatment was created and sent to 45 member institutions of the Pediatric Epilepsy Research Consortium (PERC). Results were analyzed by a working group of PERC focused on IESS. Results: Thirty‐three institutions completed the survey. Most institutions (91%) managed new‐onset IESS in‐patient, with 76% using overnight video EEG (vEEG) monitoring for diagnosis. Nearly all (> 90%) obtained an MRI brain and genetic testing at initial diagnosis. The most common modalities of genetic evaluation were an epilepsy panel (47%) and trio whole exome sequencing (44%). For assessment of response at the first follow‐up, 45% used extended vEEG (1–6 h), with 36% continuing to obtain overnight vEEG. The 2021 BASED score (Burden of Amplitude and Epileptiform Discharges) was the preferred method of assessing response (58%) compared to resolution of hypsarrhythmia (39%). High‐dose prednisolone was the first treatment for most institutions, irrespective of the etiology (apart from Tuberous Sclerosis Complex). Combined treatment (hormonal + vigabatrin) was less commonly used as first treatment (9%–12%, depending on etiology). Most institutions (63%) looked for failure of both hormonal therapy and vigabatrin (sequential or combined) before pursuing surgical treatment in patients with identifiable brain MRI lesions, but would also consider surgical treatment in patients with remission of electro‐clinical epileptic spasms but continued epileptiform EEGs. Significance: There are areas of consensus and variability in management of IESS in US institutions. Updated consensus guidelines addressing the comprehensive management of IESS are needed to help standardize and optimize care in these patients. Plain Language Summary: Infantile Epileptic Spasms Syndrome requires prompt diagnosis and initiation of appropriate treatment to improve developmental outcomes. In this survey of tertiary pediatric centers in the United States, we found areas of consensus (use of overnight video EEG at initial diagnosis, use of high‐dose prednisolone as initial treatment, preference for sequential as opposed to combination therapy, use of the 2021 BASED score for EEG evaluation, and the early consideration of epilepsy surgery) and variability (type of genetic testing for diagnosis, choice of second and third treatments, use of antiseizure medications for persistently epileptic EEG) in management of these patients.
- 21 February 2026
- Published by Elsevier in Epilepsy & Behavior
- Vol. 178, 110966
Identification of lateralized cognitive profiles in surgical and nonsurgical pediatric epilepsy patients using the Cognitive Lateralization Rating Index
- 21 February 2026
- Published by Elsevier in Epilepsy & Behavior
- Vol. 178, 110966
Identification of lateralized cognitive profiles in surgical and nonsurgical pediatric epilepsy patients using the Cognitive Lateralization Rating Index
- 10 October 2025
- Published by Elsevier in Pediatric Neurology
- Vol. 174, 46-53
Treatment Practices for Infantile Epileptic Spasms Syndrome: Consensus and Variation in Major Pediatric Epilepsy Centers
- 10 October 2025
- Published by Elsevier in Pediatric Neurology
- Vol. 174, 46-53
Treatment Practices for Infantile Epileptic Spasms Syndrome: Consensus and Variation in Major Pediatric Epilepsy Centers
- 15 August 2025
- Published by Elsevier in Pediatric Neurology
- Vol. 172, 78-85
EEG Scoring Systems in Developmental Epileptic Encephalopathies With and Without Epileptic Spasms: A Comparative Analysis of Reliability and Diagnostic Clarity
- 15 August 2025
- Published by Elsevier in Pediatric Neurology
- Vol. 172, 78-85
EEG Scoring Systems in Developmental Epileptic Encephalopathies With and Without Epileptic Spasms: A Comparative Analysis of Reliability and Diagnostic Clarity
Evaluating the effectiveness of medical therapy in infantile epileptic spasms syndrome due to surgically‐remediable lesions
Objective: This single‐center retrospective study examined the response to initial standard therapy in children with infantile epileptic spasms syndrome (IESS) associated with surgically‐remediable lesion and evaluated the risk factors for drug resistance. We assessed whether the failure of the first standard therapy for surgically‐remediable IESS predicted eventual drug resistance. Methods: New‐onset IESS with surgically‐remediable lesions was included. Regression analysis was performed to identify risk factors for drug resistance. Kaplan–Meier survival analysis stratified by the response to first standard therapy was conducted to explore if earlier recognition of drug‐resistant epilepsy (DRE) was possible. Results: We identified 61 patients (57% female) with IESS and surgically‐remediable lesion (median follow‐up of 52 months). First standard treatment started at a median of 15 days after IESS onset resulted in favorable initial response in 31%. Response rate to second standard therapy among those who failed first treatment was 53%, with an overall response rate to sequential standard therapy of 63.8%. Relapses (epileptic spasms/focal seizures) were frequent (59%). At last follow‐up, 41% ( n = 25) remained drug responsive. The cumulative proportion of survival free of drug resistance was 57% at 2 months, dropping to 38% at 36 months after IESS diagnosis. The odds for DRE increased with extensive magnetic resonance imaging (MRI) abnormality (odds ratio [OR] = 38.5) and congenital‐structural abnormality (OR = 23.3) and decreased with older age at IESS onset (OR = 0.68). Kaplan–Meier survival curve differed significantly between responders and non‐responders to first standard therapy ( p = .02). In the drug‐resistant group ( n = 36), 34 underwent surgery with Engel class I outcome in 76.5%. Significance: Although two‐thirds of surgically‐remediable IESS exhibited an initial response to medical therapy, relapses were frequent. The majority progressed to DRE during follow‐up, particularly those with younger age at IESS onset, congenital‐structural etiology, or extensive MRI abnormalities. Patients at risk for DRE can be recognized early by the lack of response to first standard therapy (OR 4.15). Our findings can help reduce delays for surgical referral in patients with surgically‐remediable IESS.
Evaluating the effectiveness of medical therapy in infantile epileptic spasms syndrome due to surgically‐remediable lesions
Objective: This single‐center retrospective study examined the response to initial standard therapy in children with infantile epileptic spasms syndrome (IESS) associated with surgically‐remediable lesion and evaluated the risk factors for drug resistance. We assessed whether the failure of the first standard therapy for surgically‐remediable IESS predicted eventual drug resistance. Methods: New‐onset IESS with surgically‐remediable lesions was included. Regression analysis was performed to identify risk factors for drug resistance. Kaplan–Meier survival analysis stratified by the response to first standard therapy was conducted to explore if earlier recognition of drug‐resistant epilepsy (DRE) was possible. Results: We identified 61 patients (57% female) with IESS and surgically‐remediable lesion (median follow‐up of 52 months). First standard treatment started at a median of 15 days after IESS onset resulted in favorable initial response in 31%. Response rate to second standard therapy among those who failed first treatment was 53%, with an overall response rate to sequential standard therapy of 63.8%. Relapses (epileptic spasms/focal seizures) were frequent (59%). At last follow‐up, 41% ( n = 25) remained drug responsive. The cumulative proportion of survival free of drug resistance was 57% at 2 months, dropping to 38% at 36 months after IESS diagnosis. The odds for DRE increased with extensive magnetic resonance imaging (MRI) abnormality (odds ratio [OR] = 38.5) and congenital‐structural abnormality (OR = 23.3) and decreased with older age at IESS onset (OR = 0.68). Kaplan–Meier survival curve differed significantly between responders and non‐responders to first standard therapy ( p = .02). In the drug‐resistant group ( n = 36), 34 underwent surgery with Engel class I outcome in 76.5%. Significance: Although two‐thirds of surgically‐remediable IESS exhibited an initial response to medical therapy, relapses were frequent. The majority progressed to DRE during follow‐up, particularly those with younger age at IESS onset, congenital‐structural etiology, or extensive MRI abnormalities. Patients at risk for DRE can be recognized early by the lack of response to first standard therapy (OR 4.15). Our findings can help reduce delays for surgical referral in patients with surgically‐remediable IESS.
- Open Access
- 20 November 2024
- Published by Wiley in Annals of the Child Neurology Society
- Vol. 2 (4) , 299-302
GRIN1‐related epilepsy in a neonate with response to memantine and vigabatrin
Objective: A newborn with GRIN1‐related early infantile developmental and epileptic encephalopathy (DEE) with striking pharmacoresistance is described with emphasis on potential therapy with memantine and vigabatrin.Methods: The term neonate manifested electrographic and electroclinical seizures from the first day of life with focal tonic seizures with apnea, bradycardia, and desaturations and later developed epileptic spasms and a hyperkinetic movement disorder. Multiple antiseizure medication trials were unsuccessful. Brain magnetic resonance imaging displayed extensive malformations of cortical development.Results: Whole‐exome sequencing demonstrated a de novo novel GRIN1 variant (1916T > G,p.Phe639Cys), which can be associated with NMDA receptor dysfunction. Gain‐of‐function mutation was suspected based on phenotype correlation. Seizures markedly improved after initiation of memantine, an NMDA‐receptor antagonist. Memantine was complemented by the concurrent use of vigabatrin, initiated 4 days earlier due to emergence of epileptic spasms. Significant reduction in seizures facilitated discharge from neonatal intensive care unit.Interpretation: GRIN1‐related disorders occur due to NMDA receptor dysfunction. Patients with gain‐of‐function GRIN1 mutations who present with the phenotype of DEE with extensive bilateral polymicrogyria may benefit from a trial of NMDA‐receptor antagonist therapy and vigabatrin. Further research is warranted to better understand this markedly pharmacoresistant condition and to investigate targeted therapies in GRIN1 DEE.
- 20 November 2024
- Published by Wiley in Annals of the Child Neurology Society
- Vol. 2 (4) , 299-302
Open AccessGRIN1‐related epilepsy in a neonate with response to memantine and vigabatrin
Objective: A newborn with GRIN1‐related early infantile developmental and epileptic encephalopathy (DEE) with striking pharmacoresistance is described with emphasis on potential therapy with memantine and vigabatrin.Methods: The term neonate manifested electrographic and electroclinical seizures from the first day of life with focal tonic seizures with apnea, bradycardia, and desaturations and later developed epileptic spasms and a hyperkinetic movement disorder. Multiple antiseizure medication trials were unsuccessful. Brain magnetic resonance imaging displayed extensive malformations of cortical development.Results: Whole‐exome sequencing demonstrated a de novo novel GRIN1 variant (1916T > G,p.Phe639Cys), which can be associated with NMDA receptor dysfunction. Gain‐of‐function mutation was suspected based on phenotype correlation. Seizures markedly improved after initiation of memantine, an NMDA‐receptor antagonist. Memantine was complemented by the concurrent use of vigabatrin, initiated 4 days earlier due to emergence of epileptic spasms. Significant reduction in seizures facilitated discharge from neonatal intensive care unit.Interpretation: GRIN1‐related disorders occur due to NMDA receptor dysfunction. Patients with gain‐of‐function GRIN1 mutations who present with the phenotype of DEE with extensive bilateral polymicrogyria may benefit from a trial of NMDA‐receptor antagonist therapy and vigabatrin. Further research is warranted to better understand this markedly pharmacoresistant condition and to investigate targeted therapies in GRIN1 DEE.
- Open Access
- 13 January 2024
- Published by Wiley in Epilepsia Open
- Vol. 9 (2) , 819-822
Initial combination versus early sequential standard therapies for Infantile Epileptic Spasms Syndrome—Feedback from stakeholders
- 13 January 2024
- Published by Wiley in Epilepsia Open
- Vol. 9 (2) , 819-822
Open AccessInitial combination versus early sequential standard therapies for Infantile Epileptic Spasms Syndrome—Feedback from stakeholders
- Open Access
- 28 May 2020
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 71 (10) , 2752-2756
Asymptomatic Transmission During the Coronavirus Disease 2019 Pandemic and Implications for Public Health Strategies
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spread rapidly in a few months despite global public health strategies to curb transmission by testing symptomatic patients and social distancing. This review summarizes evidence that highlights transmission by asymptomatic and presymptomatic individuals. Viral load of asymptomatic and symptomatic cases is comparable. Viral shedding is highest before symptom onset, suggesting high transmissibility before symptoms. Within universally tested subgroups, high percentages of SARS-CoV-2 infected asymptomatic individuals were found. Asymptomatic transmission was reported in several clusters, including a Wuhan study showing an alarming rate of intrahospital transmission. Several countries reported higher prevalence among healthcare workers than general population raising concern that healthcare workers could act as silent vectors. Therefore, current strategies that rely solely on “symptom onset” for infection identification need urgent reassessment. Extensive universal testing irrespective of symptoms may be considered, with priority placed on groups with high frequency exposure to positive patients.
- 28 May 2020
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 71 (10) , 2752-2756
Open AccessAsymptomatic Transmission During the Coronavirus Disease 2019 Pandemic and Implications for Public Health Strategies
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spread rapidly in a few months despite global public health strategies to curb transmission by testing symptomatic patients and social distancing. This review summarizes evidence that highlights transmission by asymptomatic and presymptomatic individuals. Viral load of asymptomatic and symptomatic cases is comparable. Viral shedding is highest before symptom onset, suggesting high transmissibility before symptoms. Within universally tested subgroups, high percentages of SARS-CoV-2 infected asymptomatic individuals were found. Asymptomatic transmission was reported in several clusters, including a Wuhan study showing an alarming rate of intrahospital transmission. Several countries reported higher prevalence among healthcare workers than general population raising concern that healthcare workers could act as silent vectors. Therefore, current strategies that rely solely on “symptom onset” for infection identification need urgent reassessment. Extensive universal testing irrespective of symptoms may be considered, with priority placed on groups with high frequency exposure to positive patients.
- Open Access
- 26 December 2019
- Published by Springer Nature in CNS Drugs
- Vol. 34 (1) , 47-63
Pharmacotherapy for Pediatric Convulsive Status Epilepticus
Convulsive status epilepticus (CSE) is one of the most common pediatric neurological emergencies. Ongoing seizure activity is a dynamic process and may be associated with progressive impairment of gamma-aminobutyric acid (GABA)-mediated inhibition due to rapid internalization of GABAA receptors. Further hyperexcitability may be caused by AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) and NMDA (N-methyl-d-aspartic acid) receptors moving from subsynaptic sites to the synaptic membrane. Receptor trafficking during prolonged seizures may contribute to difficulties treating seizures of longer duration and may provide some of the pathophysiological underpinnings of established and refractory SE (RSE). Simultaneously, a practice change toward more rapid initiation of first-line benzodiazepine (BZD) treatment and faster escalation to second-line non-BZD treatment for established SE is in progress. Early administration of the recommended BZD dose is suggested. For second-line treatment, non-BZD anti-seizure medications (ASMs) include valproate, fosphenytoin, or levetiracetam, among others, and at this point there is no clear evidence that any one of these options is better than the others. If seizures continue after second-line ASMs, RSE is manifested. RSE treatment consists of bolus doses and titration of continuous infusions under continuous electro-encephalography (EEG) guidance until electrographic seizure cessation or burst-suppression. Ultimately, etiological workup and related treatment of CSE, including broad spectrum immunotherapies as clinically indicated, is crucial. A potential therapeutic approach for future studies may entail consideration of interventions that may accelerate diagnosis and treatment of SE, as well as rational and early polytherapy based on synergism between ASMs by utilizing medications targeting different mechanisms of epileptogenesis and epileptogenicity.
- 26 December 2019
- Published by Springer Nature in CNS Drugs
- Vol. 34 (1) , 47-63
Open AccessPharmacotherapy for Pediatric Convulsive Status Epilepticus
Convulsive status epilepticus (CSE) is one of the most common pediatric neurological emergencies. Ongoing seizure activity is a dynamic process and may be associated with progressive impairment of gamma-aminobutyric acid (GABA)-mediated inhibition due to rapid internalization of GABAA receptors. Further hyperexcitability may be caused by AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) and NMDA (N-methyl-d-aspartic acid) receptors moving from subsynaptic sites to the synaptic membrane. Receptor trafficking during prolonged seizures may contribute to difficulties treating seizures of longer duration and may provide some of the pathophysiological underpinnings of established and refractory SE (RSE). Simultaneously, a practice change toward more rapid initiation of first-line benzodiazepine (BZD) treatment and faster escalation to second-line non-BZD treatment for established SE is in progress. Early administration of the recommended BZD dose is suggested. For second-line treatment, non-BZD anti-seizure medications (ASMs) include valproate, fosphenytoin, or levetiracetam, among others, and at this point there is no clear evidence that any one of these options is better than the others. If seizures continue after second-line ASMs, RSE is manifested. RSE treatment consists of bolus doses and titration of continuous infusions under continuous electro-encephalography (EEG) guidance until electrographic seizure cessation or burst-suppression. Ultimately, etiological workup and related treatment of CSE, including broad spectrum immunotherapies as clinically indicated, is crucial. A potential therapeutic approach for future studies may entail consideration of interventions that may accelerate diagnosis and treatment of SE, as well as rational and early polytherapy based on synergism between ASMs by utilizing medications targeting different mechanisms of epileptogenesis and epileptogenicity.